DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 23, 2014--
plc. (NYSE: COV) does not infringe certain patents held by Ethicon
Endo-Surgery, Inc., a Johnson & Johnson company, according to a summary
judgment ruling issued by the U.S. District Court, Southern District of
Ohio. As a result of this ruling, the Ethicon patent infringement action
is dismissed and Covidien remains free to continue selling its
Sonicision™ cordless ultrasonic dissection system.
Ethicon sued Covidien in December 2011, claiming that Covidien’s
award-winning Sonicision system infringed a number of Ethicon patents.
In a Jan. 22 ruling, the Court found that Covidien does not infringe any
of the seven Ethicon patents in dispute, and also ruled that five of
Ethicon’s patents are invalid.
“The Court recognized that Covidien’s Sonicision system is
differentiated from the devices and intellectual property of our
competitor,” said Chris Barry, president, Advanced Surgical, Covidien.
“As we demonstrated in this case, we will vigorously protect our
innovative products, solutions and intellectual property.”
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien develops,
manufactures and sells a diverse range of industry-leading medical
device and supply products. With 2013 revenue of $10.2 billion, Covidien
has more than 38,000 employees worldwide in more than 70 countries, and
its products are sold in over 150 countries. Please visit www.covidien.com
to learn more about our business.
Source: Covidien plc.
Marguerite Copel, 203-821-4720
Lannum, CFA, 508-452-4343